Compare JRI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JRI | VNDA |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.8M | 441.5M |
| IPO Year | N/A | 2006 |
| Metric | JRI | VNDA |
|---|---|---|
| Price | $13.66 | $8.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.63 |
| AVG Volume (30 Days) | 68.0K | ★ 2.7M |
| Earning Date | 01-01-0001 | 02-12-2026 |
| Dividend Yield | ★ 9.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $212,074,000.00 |
| Revenue This Year | N/A | $12.01 |
| Revenue Next Year | N/A | $24.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.12 |
| 52 Week Low | $9.70 | $3.81 |
| 52 Week High | $12.12 | $9.60 |
| Indicator | JRI | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 60.98 |
| Support Level | $13.36 | $7.14 |
| Resistance Level | $13.79 | $7.82 |
| Average True Range (ATR) | 0.13 | 0.41 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 71.43 | 68.29 |
Nuveen Real Asset Income and Growth Fund is the United States-based closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its plan involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.